26-04-2024
|
|
|
Medicamen Biotech Limited has informed the Exchange regarding 'Completion of US FDA Inspection at the Oncology Formulation facility of Medicamen Biotech Limited at Hardwar facility'. |
|
|
|
17-04-2024
|
|
|
Medicamen Biotech Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 |
|
|
|
02-04-2024
|
|
|
Medicamen Biotech Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
|
|
|
02-04-2024
|
|
|
MEDICAMEN BIOTECH LIMITED has informed the Exchange about Closure of Trading Window |
|
|
|
27-03-2024
|
|
|
Medicamen Biotech Limited has informed the Exchange regarding Trading Plan pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
|
|
|
27-03-2024
|
|
|
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform that, Ethiopian FDA has conducted audit of Oncology Plant, Haridwar. We are awaiting the plant approval from FDA.Meanwhile we have submitted dossiers for 10 oncology products in |
|
|
|
26-03-2024
|
|
|
Medicamen Biotech Limited has informed the Exchange regarding Trading Plan pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 |
|
|
|
26-03-2024
|
|
|
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform that, Ethiopian FDA has conducted audit of Oncology Plant, Haridwar. We are awaiting the plant approval from FDA.Meanwhile we have submitted dossiers for 10 oncology products in Ethiopia.Kindly take the same on your records and oblige. |
|
|
|
26-03-2024
|
|
|
Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, we wish to inform that, Ethiopian FDA has conducted audit of Oncology Plant, Haridwar. We are awaiting the plant approval from FDA.Meanwhile we have submitted dossiers for 10 oncology products in |
|
|
|
21-03-2024
|
|
|
Medicamen Biotech Limited has informed the Exchange regarding 'Quarterly Results December 2023'. |
|
|
|
|